Investor relations / Capital & investment

FULL YEAR 2025

Investing across
the company.

Research, production and infrastructure investments sit alongside the financing choices that support Asteria’s operating model.

CAPITAL EXPENDITURE / 2025

$370million

Production, research and infrastructure across the group.

A distributed
investment program.

The 2025 capital program includes US production and packaging assets, Ireland research equipment, Singapore manufacturing expansion and UK infrastructure.

Explore the operating footprint →

AT YEAR END 2025

Financing and
financial flexibility.

External debt and cash describe different parts of the financial position. They are presented separately, not as a net-debt measure.

External debt
$5.38billion

Historical year-end debt register, not a market quotation.

Closing cash
$780million

Worldwide consolidated cash at the end of 2025.

READ THE MEASURES TOGETHER

Research expense is not
capital expenditure.

In 2025, research and development expense was $1.09 billion, while capital expenditure was $370 million. Operating cash flow was $1.37 billion. These measures describe different financial activities; they are not interchangeable.

Explore research expense →Follow cash movement →Two acquisitions, different legal outcomes →

ABOUT THIS EXPERIENCE

A fictional company.
A real invitation to explore.

Asteria Biohealth is a fictional company created for a learning and simulation experience. Its people, products, financial figures and company history belong to that authored world.

This website is a company reference for the workshop. The company overview describes the modeled full year 2025; the Ireland feature revisits an earlier chapter in January 2025. It does not offer medical advice, recruit patients, accept investments or collect submissions. No analytics run on this page.